Immunic (IMUX) Expected to Announce Earnings on Wednesday

Immunic (NASDAQ:IMUX - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Immunic Trading Down 0.5%

Shares of Immunic stock traded down $0.01 during trading on Monday, reaching $1.01. The company's stock had a trading volume of 472,712 shares, compared to its average volume of 951,820. The company has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.09. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11. The firm has a market cap of $96.30 million, a PE ratio of -0.82 and a beta of 1.73.

Wall Street Analyst Weigh In

Several research firms have commented on IMUX. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. D. Boral Capital reaffirmed a "buy" rating and set a $17.00 price target on shares of Immunic in a report on Wednesday, April 30th. B. Riley reissued a "buy" rating and issued a $6.00 price objective on shares of Immunic in a research note on Wednesday, April 16th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Thursday, May 1st. Finally, William Blair began coverage on shares of Immunic in a report on Tuesday, March 25th. They issued an "outperform" rating on the stock. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Immunic has an average rating of "Buy" and a consensus price target of $13.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.